At Higher Risk, Vaccine Efficacy, Uptake Are Crucial for Older Adult Populations | IDWeek 2024

Drug Topics October 17, 2024
Lauren Biscaldi, MS, Managing Editor

Three RSV vaccines are currently FDA approved for use in adults aged 60 or older.

Respiratory viruses don’t discriminate, but older adults are at an increased risk for respiratory tract infections. Per the CDC, most deaths due to respiratory viruses occur in individuals aged 65 years or older, with a sharp increase in risk as people age.¹

Vaccines for this population, therefore, are a crucial need. The first 2 RSV vaccines were approved in May 2023,^2,3 with an additional vaccine—Moderna’s mRESVIA—approved in May 2024.⁴ Now, researchers are beginning to evaluate the efficacy of these vaccines over time, what vaccine uptake is like by age, demographic, and socioeconomic factors, and whether combination RSV vaccines, targeting multiple lower respiratory tract threats, are...

Today's Sponsors

Today's Sponsor